Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report
Rituximab is a chimeric monoclonal antibody that targets CD-20 antigen expressed in more than 90% of all B cell non-Hodgkin's lymphoma (NHL). We report a case of 33-year-old female without any comorbidities, newly diagnosed with stage IIIB follicular lymphoma treated with rituximab-based chemot...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications & Media Pvt Ltd
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663870/ |